Doz

Secukinumab

سکوکینومب

⚠ Unverified

🎗️ Antineoplastic And Immunomodulating AgentsIL-17A inhibitor

🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:Use with caution 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA125504ATC L04AC10

Market / country: 🇺🇸 USA

Cosentyx (US)

🧮 Dose calculator

Psoriasis and steroid-responsive dermatoses · Regimen source: FDA Cosentyx · 2.3

⛔ At weeks 0, 1, 2, 3 and 4 and then every 4 weeks SC (not daily). 150 mg may be acceptable for some patients. FDA Cosentyx · 2.3

🛡️ Safety & information

Contraindications

  • ⛔ Serious hypersensitivity to secukinumab (anaphylaxis, angioedema). FDA Cosentyx · 4

Warnings

  • • Infections (TB test first); inflammatory bowel disease (exacerbation or new onset); eczematous eruptions. FDA Cosentyx · 5

Formulations

  • 150 mg/mL pen or syringe (also 300 mg/2 mL, 75 mg/0.5 mL) — injection 🇺🇸 USA FDA Cosentyx · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Cosentyx · 8.1

    “Risk Summary Limited available human data with COSENTYX use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Cosentyx · 8.2

    “There are no data on the effects of COSENTYX on the breastfed child or the effects on milk production.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Cosentyx · 8.4

    “Subcutaneous Administration Pediatric Plaque Psoriasis The safety and effectiveness of COSENTYX have been established for the treatment of moderate to severe PsO in pediatric patients aged 6 years and older who are candidates for systemic therapy or phototherapy [see Adverse Reactions (6.1) and Clinical Studies …”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cosentyx · 8.5

    “Of the 3,430 PsO subjects exposed to subcutaneous COSENTYX in clinical trials, a total of 230 (7%) were 65 years of age and older, and 32 (1%) subjects were 75 years of age and older.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav